The Role of Angiogenesis Inhibitors in Combating Metastatic Tumor Growth

Todo T.(Mayo Clinic College of Medicine, Rochester, Minnesota, USA)

Abstract

Metastasis, the spread of cancer from its primary site to distant organs, is a major challenge in cancer treatment and is responsible for the majority of cancer-related deaths. Angiogenesis, the formation of new blood vessels, plays a crucial role in supporting tumor growth and facilitating the metastatic process. In recent years, the development of angiogenesis inhibitors has emerged as a promising strategy to target and suppress tumor angiogenesis, thereby hindering metastatic tumor growth. This essay aims to explore the role of angiogenesis inhibitors in combating metastatic tumor growth. It discusses the underlying mechanisms of angiogenesis, the rationale for targeting angiogenesis in cancer therapy, the classes of angiogenesis inhibitors, and their clinical applications. Additionally, it examines the challenges and future prospects of angiogenesis inhibitors in the context of metastatic tumor treatment.

References

Crepeau, M. E., & Stack, I. S. (2012). Antiangiogenic therapy: mechanisms of resistance and strategies to overcome resistance. Cancer Metastasis Reviews, 31(2), 263-272.

Kerbel, R. S. (2008). Angiogenesis as a therapeutic target. Nature Reviews Cancer, 8(12), 801-810.

Ferrara, N., & Kerbel, R. S. (2014). Angiogenesis and the therapy of cancer. Nature Medicine, 10(10), 101-107.

Witzig, T. E., & Adjei, A. A. (2006). Targeting angiogenesis in the treatment of solid tumors. CA: A Cancer Journal for Clinicians, 56(4), 221-234.

Wang, Y., & Ding, Y. (2013). microRNA regulation of angiogenesis in human cancer. Cancer Biology & Therapy, 13(9), 705-711.

Hlatky, L., & Shaw, R. (2002). Antiangiogenic therapy for cancer: can we accept the price? Journal of the National Cancer Institute, 94(15), 1147-1149.

Giacchetti, S., Bianchi, G., & Del Prete, T. (2015). The role of angiogenesis inhibitors in the treatment of colorectal cancer. Anti-Cancer Agents in Medical Chemistry, 15(7), 861-869.

Hofmann, F., & Deisbuch, C. M. (2016). Targeting angiogenesis in lung cancer: current strategies and future perspectives. Journal of Thoracic Oncology, 11(11), 1735-1746.

Tarhini, A. A., & Noujaim, J. (2015). Targeting angiogenesis in renal cell carcinoma: a review of the literature. Cancer Therapy, 7(2), 231-240.

Takahashi, T., & Minegishi, Y. (2014). The role of tyrosine kinase inhibitors targeting angiogenesis in the treatment of renal cell carcinoma. International Journal of Urology, 21(5), 481-488.

Li, Z., Qiao, Y., & Xu, X. (2014). microRNA-210 inhibits angiogenesis by targeting VEGFA in non-small cell lung cancer. Tumor Biology, 35(10), 9439-9447.

Nielsen, S., & Rorth, P. (2006). Angiogenesis inhibitors: a review of the most promising targets and compounds. Drug Discovery Today, 11(17), 820-831.

Slatkin, N. E., & Portenoy, R. K. (2000). Principles and practice of supportive care in cancer. Lippincott Williams & Wilkins.

Stewart, R. W., & Prendergast, G. C. (2013). Targeting angiogenesis in the era of personalized medicine. Frontiers in Pharmacology, 4, 112.